HER2-low status in inflammatory breast cancer (IBC) is associated with hormone receptors positivity but not with pathological response to neoadjuvant chemotherapy or overall survival

被引：0
|
作者：
de Nonneville, Alexandre
Finetti, Pascal
Boudin, Laurys
Usclade, Lucas
Viens, Patrice
Viret, Frederic
Mamessier, Emilie
Goncalves, Anthony
Bertucci, Francois
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-02-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-02-07
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Tumor-Associated Lymphocytes and Hormone Receptor Status Predict Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer
    Jin, L. Hee
    Jin-Hee, A.
    Young, S. Jin
    Sei-hyun, A.
    Gyungyub, G.
    CANCER RESEARCH, 2010, 70
  • [32] HER2-low breast cancer: insights on pathological testing
    Liu, Yueping
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [33] Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
    Xia, Lin-Yu
    Cao, Xu-Chen
    Yu, Yue
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [34] HER2-Low Breast Cancer: Pathological and Clinical Landscape
    Tarantino, Paolo
    Hamilton, Erika
    Tolaney, Sara M.
    Cortes, Javier
    Morganti, Stefania
    Ferraro, Emanuela
    Marra, Antonio
    Viale, Giulia
    Trapani, Dario
    Cardoso, Fatima
    Penault-Llorca, Frederique
    Viale, Giuseppe
    Andre, Fabrice
    Curigliano, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (17) : 1951 - +
  • [35] Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy
    Kang, Sora
    Lee, So H.
    Lee, Hee J.
    Jeong, Hyehyun
    Jeong, Jae H.
    Kim, Jeong E.
    Ahn, Jin-Hee
    Jung, Kyung H.
    Gong, Gyungyub
    Kim, Hak H.
    Lee, Saebyeol
    Lee, Jongwon
    Kim, Sung-Bae
    EUROPEAN JOURNAL OF CANCER, 2022, 176 : 30 - 40
  • [36] Analyzing Neoadjuvant Chemotherapy Effects in HER2-Low Breast Cancer: Real World Data
    Antonini, Marcelo
    Mattar, Andre
    Richter, Fernanda G.
    Ramos, Marcellus N.
    Teixeira, Marina D.
    Pantarotto, Nathalia N.
    Matta, Nadia F.
    Amorim, Andressa G.
    Pinheiro, Denise J.
    Lopes, Reginaldo C.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [37] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [38] Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
    Shao, Yingbo
    Guan, Huijuan
    Luo, Zhifen
    Yu, Yang
    He, Yaning
    Chen, Qi
    Liu, Chaojun
    Zhu, Fangyuan
    Liu, Hui
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [39] The Pathological Response of Her2+Breast Cancer with Neoadjuvant Chemotherapy and Radiation Therapy
    Chao, M.
    Baker, C.
    Jassal, S.
    Law, M.
    Bevington, E.
    Stoney, D.
    Zantuck, N.
    Chew, G.
    Loh, S. W.
    Hyett, A.
    Guerrieri, M.
    Ng, M.
    Cokelek, M.
    Neoh, D.
    Yong, C.
    Ho, H.
    Tacey, M.
    Joon, D. Lim
    Khor, R.
    Foroudi, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E17 - E17
  • [40] Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer
    Shang, Jiuyan
    Sun, Xuemei
    Xu, Zihang
    Cai, Lijing
    Liu, Chang
    Wu, Si
    Liu, Yueping
    FRONTIERS IN ONCOLOGY, 2023, 13
12345